Thyroid cancer - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Thyroid cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Thyroid cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Thyroid cancer: Overview
Thyroid cancer is a disease in which malignant (cancer) cells form in the tissues of the thyroid gland. Thyroid nodules are common but usually are not cancer. There are different types of thyroid cancer. Age, gender, and being exposed to radiation can affect the risk of thyroid cancer. Medullary thyroid cancer is sometimes caused by a change in a gene that is passed from parent to child. Signs of thyroid cancer include a swelling or lump in the neck. Tests that examine the thyroid, neck, and blood are used to diagnose thyroid cancer. Certain factors affect prognosis (chance of recovery) and treatment options.
'Thyroid cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Thyroid cancer pipeline landscape is provided which includes the disease overview and Thyroid cancer treatment guidelines. The assessment part of the report embraces, in depth Thyroid cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Thyroid cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Thyroid cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Thyroid cancer Emerging Drugs
Further product details are provided in the report..
Thyroid cancer: Therapeutic Assessment
This segment of the report provides insights about the different Thyroid cancer drugs segregated based on following parameters that define the scope of the report, such as:
Thyroid cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Thyroid cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Thyroid cancer drugs.
Thyroid cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Thyroid cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Thyroid cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Thyroid cancer: Overview
Thyroid cancer is a disease in which malignant (cancer) cells form in the tissues of the thyroid gland. Thyroid nodules are common but usually are not cancer. There are different types of thyroid cancer. Age, gender, and being exposed to radiation can affect the risk of thyroid cancer. Medullary thyroid cancer is sometimes caused by a change in a gene that is passed from parent to child. Signs of thyroid cancer include a swelling or lump in the neck. Tests that examine the thyroid, neck, and blood are used to diagnose thyroid cancer. Certain factors affect prognosis (chance of recovery) and treatment options.
'Thyroid cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Thyroid cancer pipeline landscape is provided which includes the disease overview and Thyroid cancer treatment guidelines. The assessment part of the report embraces, in depth Thyroid cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Thyroid cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Thyroid cancer R&D. The therapies under development are focused on novel approaches to treat/improve Thyroid cancer.
This segment of the Thyroid cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Thyroid cancer Emerging Drugs
- Donafenib: Suzhou Zelgen Biopharmaceuticals
- Anlotinib: Jiangsu Chia-Tai Tianqing Pharmaceutical
- Ponatinib: Takeda
- Nivolumab: Bristol-Myers Squibb
Further product details are provided in the report..
Thyroid cancer: Therapeutic Assessment
This segment of the report provides insights about the different Thyroid cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Thyroid cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Thyroid cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Thyroid cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Thyroid cancer drugs.
Thyroid cancer Report Insights
- Thyroid cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Thyroid cancer drugs?
- How many Thyroid cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Thyroid cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Thyroid cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Thyroid cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Suzhou Zelgen Biopharmaceuticals
- Jiangsu Chia-Tai Tianqing Pharmaceutical
- Takeda
- Bristol-Myers Squibb
- Genentech
- AffyImmune Therapeutics, Inc.
- Taizhou Hanzhong biomedical co. LTD
- NantCell, Inc.
- Bayer
- Merck Sharp & Dohme Corp.
- Pfizer
- MedImmune LLC
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Eisai Inc.
- cCAM Biotherapeutics
- Purple Biotech Ltd.
- Turning Point Therapeutics, Inc.
- Hoffmann-La Roche
- Bicara Therapeutics
- Novartis
- GlobeImmune
- GE Healthcare
- IBC Pharmaceuticals
- Debiopharm
- Blueprint Medicines
- Ono Pharmaceutical
- Array BioPharma
- Hutchison MediPharma
- Celldex Therapeutics Inc
- VBL Therapeutics
- Biovista
- Donafenib
- Anlotinib
- Ponatinib
- Nivolumab
- Atezolizumab
- AIC100
- HX008
- GI-6207
- Ipilimumab
- Regorafenib
- MLN0128
- Pembrolizumab
- SU011248
- Durvalumab
- HA121-28
- Ifosfamide
- CM-24
- ETBX-011
- TPX-0046
- Entrectinib
- BCA101
- Spartalizumab
- GI 6207
- EMI 137
- Abemaciclib
- DEBIO 1124
- Gavreto
- Encorafenib
- Binimetinib
- Surufatinib
- CDX-3379
- VB-111
- BVA 701
Introduction
Executive Summary
Thyroid cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Thyroid cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Thyroid cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Thyroid cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Donafenib: Suzhou Zelgen Biopharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Ponatinib: Takeda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
AIC100: AffyImmune Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Thyroid cancer Key Companies
Thyroid cancer Key Products
Thyroid cancer- Unmet Needs
Thyroid cancer- Market Drivers and Barriers
Thyroid cancer- Future Perspectives and Conclusion
Thyroid cancer Analyst Views
Thyroid cancer Key Companies
Appendix
Executive Summary
Thyroid cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Thyroid cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Thyroid cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Thyroid cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Donafenib: Suzhou Zelgen Biopharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Ponatinib: Takeda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
AIC100: AffyImmune Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Thyroid cancer Key Companies
Thyroid cancer Key Products
Thyroid cancer- Unmet Needs
Thyroid cancer- Market Drivers and Barriers
Thyroid cancer- Future Perspectives and Conclusion
Thyroid cancer Analyst Views
Thyroid cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Thyroid cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Thyroid cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Thyroid cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Thyroid cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
